|
1
|
National Cancer Institute, . Surveillance, Epidemiology, and End Results (SEER) Program: Cancer Stat Facts: NHL — Follicular Lymphoma. https://seer.cancer.gov/statfacts/html/follicular.htmlOctober 27–2021
|
|
2
|
Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, Malpas JS and Lister TA: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol. 4:1470–1480. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC and Plumas J: In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 101:949–954. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clynes RA, Towers TL, Presta LG and Ravetch JV: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 6:443–446. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P and Watier H: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 99:754–758. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Seyfizadeh N, Seyfizadeh N, Hasenkamp J and Huerta-Yepez S: A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Crit Rev Oncol Hematol. 97:275–290. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scott DW and Gascoyne RD: The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 14:517–534. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dilek I, Ayakta H, Demir C, Meral C and Ozturk M: CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol. 27:51–55. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fehm T, Beck E, Valerius T, Gramatzki M and Jäger W: CA 125 elevations in patients with malignant lymphomas. Tumour Biol. 19:283–289. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lazzarino M, Orlandi E, Klersy C, Astori C, Brusamolino E, Corso A, Bellio L, Gargantini L, Morra E and Bernasconi C: Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: Correlation with tumor parameters and disease activity. Cancer. 82:576–582. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gutiérrez A, Martínez-Serra J, Barceló B, Sampol A, Viñas L, González G, Bea MD, Amat JC, Martín J, Ramos R, et al: Prognostic value of serum CA125 levels in diffuse large B-cell lymphoma: Potential role of a new sex- and age-adjusted reference value. Int J Lab Hematol. 32:582–589. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Memar B, Aledavood A, Shahidsales S, Ahadi M, Farzadnia M, Raziee HR, Noori S, Tayebi-Meybodi N, Amouian S and Mohtashami S: The prognostic role of tumor marker CA-125 in B-cell non-Hodgkin's lymphoma. Iran J Cancer Prev. 8:42–46. 2015.PubMed/NCBI
|
|
13
|
Kline JB, Kennedy RP, Albone E, Chao Q, Fernando S, McDonough JM, Rybinski K, Wang W, Somers EB, Schweizer C, et al: Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement. Oncotarget. 8:52045–52060. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vergote I, Armstrong D, Scambia G, Teneriello M, Sehouli J, Schweizer C, Weil SC, Bamias A, Fujiwara K, Ochiai K, et al: A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J Clin Oncol. 34:2271–2278. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nicolaides NC, Schweizer C, Somers EB, Wang W, Fernando S, Ross EN, Grasso L, Hassan R and Kline JB: CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients. Cancer Biol Ther. 19:622–630. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin J, Spidel JL, Maddage CJ, Rybinski KA, Kennedy RP, Krauthauser CL, Park YC, Albone EF, Jacob S, Goserud MT, et al: The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biol Ther. 14:1032–1038. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, et al: Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 7:62007.PubMed/NCBI
|
|
18
|
Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, et al: Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 7:202007.PubMed/NCBI
|
|
19
|
Kline JB, Fernando S, Ross EN, Grasso L and Nicolaides NC: Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding. Eur J Immunol. 48:1872–1882. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weng WK and Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 21:3940–3947. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, et al: Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood. 110:2561–2564. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Procházka V, Faber E, Raida L, Kapitáňová Z, Langová K, Indrák K and Papajík T: High serum carbohydrate antigen-125 (CA-125) level predicts poor outcome in patients with follicular lymphoma independently of the FLIPI score. Int J Hematol. 96:58–64. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Painter RH, Foster DB, Gardner B and Hughes-Jones NC: Functional affinity constants of subfragments of immunoglobulin G for Clq. Mol Immunol. 19:127–131. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chappel MS, Isenman DE, Everett M, Xu YY, Dorrington KJ and Klein MH: Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. Proc Natl Acad Sci USA. 88:9036–9040. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Orlandi C, Deredge D, Ray K, Gohain N, Tolbert W, DeVico AL, Wintrode P, Pazgier M and Lewis GK: Antigen-induced allosteric changes in a human IgG1 Fc increase low-affinity Fcγ receptor binding. Structure. 28:516–527.e5. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dam TK, Torres M, Brewer CF and Casadevall A: Isothermal titration calorimetry reveals differential binding thermodynamics of variable region-identical antibodies differing in constant region for a univalent ligand. J Biol Chem. 283:31366–31370. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pritsch O, Magnac C, Dumas G, Bouvet JP, Alzari P and Dighiero G: Can isotype switch modulate antigen-binding affinity and influence clonal selection? Eur J Immunol. 30:3387–3395. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Regep C, Georges G, Shi J, Popovic B and Deane CM: The H3 loop of antibodies shows unique structural characteristics. Proteins. 85:1311–1318. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rougé L, Chiang N, Steffek M, Kugel C, Croll TI, Tam C, Estevez A, Arthur CP, Koth CM, Ciferri C, et al: Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science. 367:1224–1230. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Denoel A, Dieude P, Chollet-Martin S and Grootenboer-Mignot S: SAT0181 immunogenicity of rituximab in patients with rheumatoid arthritis: A kinetic analysis. Ann Rheum Dis. 74 (Suppl≈2):S720.2–720. 2015. View Article : Google Scholar
|
|
31
|
Dhanda SK, Karosiene E, Edwards L, Grifoni A, Paul S, Andreatta M, Weiskopf D, Sidney J, Nielsen M, Peters B and Sette A: Predicting HLA CD4 immunogenicity in human populations. Front Immunol. 9:13692018. View Article : Google Scholar : PubMed/NCBI
|
